Healthcare [ 11/13 ] | Biotechnology [ 98/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -0.6 Increased by +11.76% | -0.72 Increased by +16.67% |
| Aug 9, 23 | -0.67 Increased by +22.99% | -0.62 Decreased by -8.06% |
| May 10, 23 | -0.57 Increased by +13.64% | -0.58 Increased by +1.72% |
| Mar 28, 23 | -0.52 Increased by +32.47% | -0.71 Increased by +26.76% |
| Nov 9, 22 | -0.68 Increased by +50% | -0.74 Increased by +8.11% |
| Aug 10, 22 | -0.87 Increased by +35.56% | -0.75 Decreased by -16% |
| May 12, 22 | -0.66 Increased by +51.11% | -0.71 Increased by +7.04% |
| Mar 17, 22 | -0.77 Increased by +48.67% | -0.98 Increased by +21.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 5.96 M Increased by +40.38% | -16.3 M Decreased by -22.4% | Decreased by -273.57% Increased by +12.81% |
| Jun 30, 23 | 6.2 M Increased by +80.45% | -17.97 M Increased by +1.63% | Decreased by -289.76% Increased by +45.49% |
| Mar 31, 23 | 5.87 M Increased by +154.31% | -13.68 M Increased by +1.59% | Decreased by -233.15% Increased by +61.3% |
| Dec 31, 22 | 5.23 M Increased by +422.7% | -13.91 M Increased by +13% | Decreased by -266.16% Increased by +83.35% |
| Sep 30, 22 | 4.25 M Increased by +N/A% | -13.32 M Increased by +84.71% | Decreased by -313.76% Decreased by N/A% |
| Jun 30, 22 | 3.44 M Increased by +N/A% | -18.27 M Decreased by -314.46% | Decreased by -531.54% Decreased by N/A% |
| Mar 31, 22 | 2.31 M Increased by +N/A% | -13.9 M Decreased by -212.94% | Decreased by -602.51% Decreased by N/A% |
| Dec 31, 21 | 1 M Decreased by -92.86% | -15.99 M Decreased by -238.94% | Decreased by -1.6 K% Decreased by -4.65 K% |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.